Invest in

Drug-Patent Cliffs

24.8%
14.6%
0.3%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
24.8%
14.6%
0.3%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 19.2%
20.3% Taro Pharmaceutical Industries Ltd. TARO 24.3%
16.8% Dr. Reddy's Laboratories Ltd RDY 31.9%
13.0% Akorn Inc. AKRX 10.7%
12.9% Mylan N.V. MYL 37.7%
11.3% Abbott Laboratories ABT 13.9%
8.3% The Medicines Company MDCO 6.4%
7.6% Impax Laboratories Inc. IPXL 23.8%
3.0% Lannett Co Inc LCI 50.6%
2.6% Mallinckrodt plc MNK 54.6%
2.0% Teva Pharmaceutical Industries Limited American Depositary Share TEVA 66.4%
1.2% Cambrex Corporation CBM 14.1%
0.9% Endo International PLC ENDP 61.9%

Quotes delayed 15 mins. Currently Aug 20, 2017 10:43:02 PM. Fields are marked with -- when data is unavailable.